H3 receptor antagonist for use in the treatment of alzheimer's disease
AssigneeSanofi
InventorsPascal Barneoud, Veronique Blanchard-Bregeon, Veronique Mary, Jean Menager, Philippe Delay-Goyet, Mathilde Lopez-Grancha, Thomas Rooney, Nathalie Schussler
Life of this patent
Estimating the term…
Abstract
This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.
Claims19
A method of delaying the disease progression of a tauopathy or related neurodegenerative disease, comprising administering to a patient in need thereof 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide or a pharmaceutically acceptable salt thereof;
- and wherein abnormal tau hyperphosphorylation or abnormal tau aggregation in said patient is thereby inhibited.
Dependencies are inferred from the claim text.